Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ASND NASDAQ:IONS NASDAQ:SDGR NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.73+1.6%$23.31$13.40▼$26.65$3.61B0.752.16 million shs1.62 million shsASNDAscendis Pharma A/S$201.01-0.8%$199.85$118.03▼$216.45$12.51B0.41478,606 shs240,533 shsIONSIonis Pharmaceuticals$71.50$60.38$23.95▼$74.42$11.40B0.332.07 million shs1.61 million shsSDGRSchrodinger$21.96+5.6%$19.78$16.60▼$28.47$1.53B1.741.23 million shs1.35 million shsUTHRUnited Therapeutics$426.21+1.1%$395.28$266.98▼$459.48$19.02B0.66696,629 shs453,275 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+1.59%+5.38%-7.92%-6.54%+52.06%ASNDAscendis Pharma A/S-0.83%-2.91%+3.62%+20.03%+57.42%IONSIonis Pharmaceuticals0.00%-2.15%+14.27%+69.27%+86.10%SDGRSchrodinger+5.63%+8.12%+15.22%-1.21%+21.19%UTHRUnited Therapeutics+1.08%-1.50%-1.81%+39.97%+20.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.73+1.6%$23.31$13.40▼$26.65$3.61B0.752.16 million shs1.62 million shsASNDAscendis Pharma A/S$201.01-0.8%$199.85$118.03▼$216.45$12.51B0.41478,606 shs240,533 shsIONSIonis Pharmaceuticals$71.50$60.38$23.95▼$74.42$11.40B0.332.07 million shs1.61 million shsSDGRSchrodinger$21.96+5.6%$19.78$16.60▼$28.47$1.53B1.741.23 million shs1.35 million shsUTHRUnited Therapeutics$426.21+1.1%$395.28$266.98▼$459.48$19.02B0.66696,629 shs453,275 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+1.59%+5.38%-7.92%-6.54%+52.06%ASNDAscendis Pharma A/S-0.83%-2.91%+3.62%+20.03%+57.42%IONSIonis Pharmaceuticals0.00%-2.15%+14.27%+69.27%+86.10%SDGRSchrodinger+5.63%+8.12%+15.22%-1.21%+21.19%UTHRUnited Therapeutics+1.08%-1.50%-1.81%+39.97%+20.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$29.3334.99% UpsideASNDAscendis Pharma A/S 2.94Moderate Buy$249.8024.27% UpsideIONSIonis Pharmaceuticals 2.80Moderate Buy$78.509.79% UpsideSDGRSchrodinger 2.38Hold$26.2919.70% UpsideUTHRUnited Therapeutics 2.57Moderate Buy$461.628.31% UpsideCurrent Analyst Ratings BreakdownLatest ACAD, UTHR, SDGR, IONS, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025ACADACADIA PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$33.0010/20/2025UTHRUnited TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$414.0010/17/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$271.0010/16/2025IONSIonis PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$86.00 ➝ $90.0010/16/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/14/2025ACADACADIA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/14/2025SDGRSchrodingerWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/13/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$203.00 ➝ $254.0010/10/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$328.00 ➝ $435.0010/9/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $264.0010/8/2025IONSIonis PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$84.00 ➝ $90.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M3.83$0.72 per share30.35$4.40 per share4.94ASNDAscendis Pharma A/S$393.54M31.51N/AN/A($1.88) per share-106.92IONSIonis Pharmaceuticals$705M16.17N/AN/A$3.73 per share19.17SDGRSchrodinger$207.54M7.79N/AN/A$5.78 per share3.80UTHRUnited Therapeutics$2.88B6.68$28.70 per share14.85$144.34 per share2.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3316.3428.597.3921.80%14.69%9.41%11/5/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$5.16N/A837.54N/A-54.94%N/A-24.31%11/13/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$1.84N/AN/AN/A-28.25%-45.29%-8.99%10/29/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/5/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.6216.6415.504.6040.36%18.73%16.49%10/29/2025 (Estimated)Latest ACAD, UTHR, SDGR, IONS, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ASNDAscendis Pharma A/S-$0.49N/AN/AN/AN/AN/A11/5/2025Q3 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$276.52 millionN/A11/5/2025Q3 2025SDGRSchrodinger-$0.72N/AN/AN/A$50.51 millionN/A10/29/2025Q3 2025IONSIonis Pharmaceuticals-$1.15N/AN/AN/A$131.75 millionN/A10/29/2025Q3 2025UTHRUnited Therapeutics$6.75N/AN/AN/A$812.87 millionN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million7/30/2025Q2 2025IONSIonis Pharmaceuticals$0.19$0.70+$0.51$0.70$270.90 million$452.00 million7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.912.83ASNDAscendis Pharma A/SN/A1.020.69IONSIonis Pharmaceuticals0.992.872.86SDGRSchrodingerN/A3.303.30UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ASNDAscendis Pharma A/SN/AIONSIonis Pharmaceuticals93.86%SDGRSchrodinger79.05%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%ASNDAscendis Pharma A/S40.00%IONSIonis Pharmaceuticals2.60%SDGRSchrodinger21.00%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510168.71 million124.00 millionOptionableASNDAscendis Pharma A/S1,01761.69 million37.02 millionOptionableIONSIonis Pharmaceuticals1,069159.39 million155.25 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableACAD, UTHR, SDGR, IONS, and ASND HeadlinesRecent News About These CompaniesMartine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) StockOctober 23 at 7:48 PM | marketbeat.comUnited Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseOctober 22 at 11:06 AM | zacks.comWhy Investors Need to Take Advantage of These 2 Medical Stocks NowOctober 22 at 9:50 AM | zacks.comTFB Advisors LLC Raises Stock Position in United Therapeutics Corporation $UTHROctober 22 at 8:19 AM | marketbeat.comNordea Investment Management AB Acquires 3,664 Shares of United Therapeutics Corporation $UTHROctober 22 at 4:21 AM | marketbeat.comUnited Therapeutics (UTHR) Expected to Announce Earnings on WednesdayOctober 22 at 4:06 AM | marketbeat.comIf You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much TodayOctober 21 at 10:28 PM | benzinga.comUnited Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 SharesOctober 21 at 4:49 PM | marketbeat.comChevy Chase Trust Holdings LLC Acquires 5,393 Shares of United Therapeutics Corporation $UTHROctober 21 at 4:17 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 SharesOctober 21 at 4:02 AM | insidertrades.comCwm LLC Boosts Stake in United Therapeutics Corporation $UTHROctober 21 at 3:24 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $1,698,360.00 in StockOctober 20, 2025 | marketbeat.comPaul Mahon Sells 11,000 Shares of United Therapeutics (NASDAQ:UTHR) StockOctober 20, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Coverage Initiated at Wells Fargo & CompanyOctober 20, 2025 | marketbeat.comAllianz Asset Management GmbH Sells 3,486 Shares of United Therapeutics Corporation $UTHROctober 20, 2025 | marketbeat.comVIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in United Therapeutics Corporation $UTHROctober 19, 2025 | marketbeat.comEnvestnet Portfolio Solutions Inc. Boosts Stake in United Therapeutics Corporation $UTHROctober 19, 2025 | marketbeat.comGenerali Asset Management SPA SGR Has $1.79 Million Stock Holdings in United Therapeutics Corporation $UTHROctober 18, 2025 | marketbeat.comTD Asset Management Inc Sells 15,633 Shares of United Therapeutics Corporation $UTHROctober 17, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Raises Stake in United Therapeutics Corporation $UTHROctober 17, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 SharesOctober 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Defense Stocks Surging as Ukraine Tensions DeepenBy Dan Schmidt | October 5, 2025AMD Could Double From Here—Thanks to Its Blockbuster OpenAI DealBy Thomas Hughes | October 7, 2025Why Wall Street Is Betting Billions on Oklo's Nuclear VisionBy Jeffrey Neal Johnson | September 26, 2025Memes Are Back: Retail Investors Are Piling Into 3 Quantum StocksBy Dan Schmidt | September 29, 2025EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming SectorBy Nathan Reiff | October 7, 2025ACAD, UTHR, SDGR, IONS, and ASND Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.73 +0.34 (+1.59%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$21.55 -0.18 (-0.83%) As of 10/23/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Ascendis Pharma A/S NASDAQ:ASND$201.01 -1.69 (-0.83%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$212.04 +11.03 (+5.49%) As of 10/23/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Ionis Pharmaceuticals NASDAQ:IONS$71.50 0.00 (0.00%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$72.76 +1.26 (+1.76%) As of 10/23/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Schrodinger NASDAQ:SDGR$21.96 +1.17 (+5.63%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$21.90 -0.06 (-0.28%) As of 10/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.United Therapeutics NASDAQ:UTHR$426.21 +4.57 (+1.08%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$425.97 -0.24 (-0.06%) As of 10/23/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
